IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, Maria T. Abreu, M. Merle Elloso, Anne Fourie, Steven Fakharzadeh, Jonathan P. Sherlock, Ya Wen Yang, Daniel J. Cua, Iain B. McInnes

Research output: Contribution to journalReview articlepeer-review

Abstract

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.

Original languageEnglish
Pages (from-to)1331217
Number of pages1
JournalFrontiers in Immunology
Volume15
DOIs
StatePublished - 2024
Externally publishedYes

Keywords

  • IL-23
  • cytokine
  • immune-mediated inflammatory diseases
  • inflammatory bowel disease
  • psoriasis
  • psoriatic arthritis

Cite this